Quality statement 5: Hormone‑relapsed metastatic prostate cancer

Quality statement

People with hormone‑relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer multidisciplinary team (MDT).

Rationale

Discussion by the urological cancer MDT is a means of ensuring that an opinion from an oncologist and/or palliative care specialist is obtained. Having a variety of opinions from experts who are aware of all current treatment options means that there is a better chance to identify the best options for the person. Those options can then be discussed with the person.

Quality measures

Structure

Evidence of local arrangements to ensure that people with hormone‑relapsed metastatic disease have their treatment options discussed by the urological cancer MDT.

Data source: Local data collection and the National Prostate Cancer Audit.

Process

Proportion of people with hormone‑relapsed metastatic disease who have their treatment options discussed by the urological cancer MDT.

Numerator – the number in the denominator who have their treatment options discussed by the urological cancer MDT.

Denominator – the number of people with hormone‑relapsed metastatic prostate cancer.

Data source: Local data collection and the National Prostate Cancer Audit.

What the quality statement means for different audiences

Service providers (such as hospitals, specialist urological cancer MDTs and specialist prostate cancer services) ensure that systems are in place for people with hormone‑relapsed metastatic prostate cancer to have their treatment options discussed by the urological cancer MDT.

Healthcare professionals ensure that people with hormone‑relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer MDT.

Commissioners (such as clinical commissioning groups and NHS England area teams) monitor whether providers have systems in place to ensure that people with hormone‑relapsed metastatic prostate cancer have their treatment options discussed by the urological cancer MDT.

People with cancer that has spread outside the prostate and whose drug treatment (to block the production of hormones that help cancer cells to grow) has stopped working have their treatment options discussed by a specialist team of healthcare professionals with different kinds of expertise in prostate cancer. This is to make sure that all the different treatment options are discussed and all suitable treatments are offered.

Source guidance

Prostate cancer: diagnosis and management (2019) NICE guideline NG131, recommendation 1.5.11

Definitions of terms used in this quality statement

Hormone‑relapsed prostate cancer

Prostate cancer after failure of primary androgen deprivation therapy.

[NICE's guideline on prostate cancer, 2014 full guideline]

Urological cancer MDT

A team that includes specialists in urology, oncology, pathology, radiology, palliative care, diet and nursing.

[Adapted from NICE's guideline on prostate cancer, 2014 full guideline and the British Uro‑Oncology Group and British Association of Urological Surgeons MDT (multi-disciplinary team) guidance for managing prostate cancer]